PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31090092-6 2019 The predicted versus observed geometric mean ratio (GMR) of AUCinf for CYP2D6 substrates desipramine and metoprolol coadministered with mirabegron 100 or 160 mg once daily were 3.47 versus 3.41 and 2.97 versus 3.29, respectively, indicating that the mirabegron model can be used to predict clinical CYP2D6 inhibition. Desipramine 89-100 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 71-77 31090092-4 2019 Models predicted and verified mirabegron and desipramine (CYP2D6 substrate) and 5-HMT and ketoconazole (strong CYP3A inhibitor) DDIs. Desipramine 45-56 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 58-64 31090092-6 2019 The predicted versus observed geometric mean ratio (GMR) of AUCinf for CYP2D6 substrates desipramine and metoprolol coadministered with mirabegron 100 or 160 mg once daily were 3.47 versus 3.41 and 2.97 versus 3.29, respectively, indicating that the mirabegron model can be used to predict clinical CYP2D6 inhibition. Desipramine 89-100 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 299-305 25296725-2 2015 The study described was to assess the potential interaction between LY2603618 and cytochrome P450 isoform 2D6 (CYP2D6) substrate desipramine in patients with cancer. Desipramine 129-140 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 82-109 27440861-3 2016 Imipramine undergoes N-demethylation to form the active metabolite desipramine, and both imipramine and desipramine are converted to hydroxylated metabolites by the polymorphic enzyme CYP2D6. Desipramine 67-78 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 184-190 27440861-3 2016 Imipramine undergoes N-demethylation to form the active metabolite desipramine, and both imipramine and desipramine are converted to hydroxylated metabolites by the polymorphic enzyme CYP2D6. Desipramine 104-115 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 184-190 27440861-4 2016 The objective of the present study is to determine whether the human pharmacokinetics of desipramine following dosing of imipramine can be predicted using static and dynamic physiologically-based pharmacokinetic (PBPK) models from in vitro input data for CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) populations. Desipramine 89-100 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 255-261 27440861-9 2016 Moreover, the PBPK model was able to recover simultaneously plasma profiles of imipramine and desipramine in populations with different phenotypes of CYP2D6. Desipramine 94-105 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 150-156 26452722-11 2016 Similarly, quinidine-mediated CYP2D6 inhibition reduced clearance of dextromethorphan and desipramine by 71 and 22%, respectively. Desipramine 90-101 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 30-36 30985942-7 2019 The PBPK model predicted that the AUC for mirabegron with itraconazole (a CYP3A4 inhibitor) was 4.12-times that in healthy elderly subjects administered mirabegron alone, and predicted that the proportional change in AUC for desipramine (a CYP2D6 substrate) with mirabegron was greater than that in healthy subjects. Desipramine 225-236 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 240-246 25296725-2 2015 The study described was to assess the potential interaction between LY2603618 and cytochrome P450 isoform 2D6 (CYP2D6) substrate desipramine in patients with cancer. Desipramine 129-140 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 111-117 19995332-0 2009 Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice. Desipramine 14-25 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 66-72 24880753-4 2014 Desipramine was selected as a model drug because it is mainly metabolized by CYP2D6, which is inhibited by almorexant in vitro. Desipramine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 77-83 24880753-7 2014 Almorexant increased the exposure to desipramine 3.7-fold, suggesting that almorexant is a moderate inhibitor of desipramine metabolism through inhibition of CYP2D6. Desipramine 37-48 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 158-164 24880753-7 2014 Almorexant increased the exposure to desipramine 3.7-fold, suggesting that almorexant is a moderate inhibitor of desipramine metabolism through inhibition of CYP2D6. Desipramine 113-124 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 158-164 23221858-1 2013 The results of two single-center, two-period, open-label trials that evaluated the effects of multiple doses of desvenlafaxine on the pharmacokinetics of desipramine, a cytochrome P450 (CYP) 2D6 enzyme substrate, are presented. Desipramine 154-165 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 169-194 21976621-4 2012 The inhibition profiles of 20 known inhibitors of CYP2D6 were characterized in vitro against four clinically relevant CYP2D6 substrates (desipramine, dextromethorphan, metoprolol, and thioridazine) and bufuralol. Desipramine 137-148 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 50-56 21976621-9 2012 The in vivo sensitivities of the clinically relevant CYP2D6 substrates desipramine, dextromethorphan, and metoprolol were determined on the basis of literature drug-drug interaction (DDI) outcomes. Desipramine 71-82 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 53-59 21976621-11 2012 Finally, the magnitude of in vivo CYP2D6 DDIs caused by quinidine was predicted using desipramine, dextromethorphan, and metoprolol. Desipramine 86-97 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 34-40 19884907-1 2010 CYP2C19 converts the tricyclic antidepressant imipramine to its active metabolite desipramine, which is subsequently inactivated by CYP2D6. Desipramine 82-93 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 132-138 23486447-3 2013 These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Desipramine 46-57 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 102-108 20840444-0 2010 Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. Desipramine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 27-33 20840444-2 2010 Additional objectives were to develop a semi-mechanistic population pharmacokinetic model for desipramine, which allowed simulation of CYP2D6-mediated inhibition, when using desipramine as a probe substrate, and to evaluate certain study design elements, such as duration of desipramine pharmacokinetic sampling, required sample size and optimal pharmacokinetic sampling schedule for intermediate, extensive and ultrarapid metabolizers of CYP2D6 substrates. Desipramine 94-105 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 135-141 20840444-2 2010 Additional objectives were to develop a semi-mechanistic population pharmacokinetic model for desipramine, which allowed simulation of CYP2D6-mediated inhibition, when using desipramine as a probe substrate, and to evaluate certain study design elements, such as duration of desipramine pharmacokinetic sampling, required sample size and optimal pharmacokinetic sampling schedule for intermediate, extensive and ultrarapid metabolizers of CYP2D6 substrates. Desipramine 94-105 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 439-445 19995332-1 2009 Desipramine (DMI), a CYP2D6 probe, was used as a model drug to test whether CYP2D6-humanized (Tg-CYP2D6) and wild-type control mice could be used as preclinical animal models to identify the effects of CYP2D6 genotype/phenotype on drug metabolic profiles. Desipramine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 21-27 19995332-4 2009 Three metabolites, 2-hydroxyl-, 10-hydroxyl, and N-desmethyl-desipramine were identified in the incubations of DMI with both wild-type and Tg-CYP2D6 MLM, as well as in human CYP2D6 extensive metabolizer liver microsomes. Desipramine 111-114 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 142-148 19995332-4 2009 Three metabolites, 2-hydroxyl-, 10-hydroxyl, and N-desmethyl-desipramine were identified in the incubations of DMI with both wild-type and Tg-CYP2D6 MLM, as well as in human CYP2D6 extensive metabolizer liver microsomes. Desipramine 111-114 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 174-180 18809731-0 2008 An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Desipramine 129-140 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 116-122 19001559-0 2009 The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. Desipramine 106-117 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 76-95 19001559-3 2009 The CYP2D6 substrate desipramine (50 mg) was administered alone on day 1 and coadministered on day 6 of dosing with either desvenlafaxine or paroxetine. Desipramine 21-32 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-10 19015855-0 2009 Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Desipramine 15-26 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 40-59 19015855-4 2009 METHODS: This 2-period study in healthy subjects investigated the pharmacokinetics of a single oral 50-mg dose of the CYP2D6 substrate desipramine, first without and subsequently with a single coadministered i.v. Desipramine 135-146 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 118-124 17667959-2 2008 First, CYP2C19 converts imipramine into the active metabolite desipramine, which is then inactivated by CYP2D6. Desipramine 62-73 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 104-110 18420781-1 2008 There are documented clinical drug-drug interactions between bupropion and the CYP2D6-metabolized drug desipramine resulting in marked (5-fold) increases in desipramine exposure. Desipramine 103-114 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 18420781-1 2008 There are documented clinical drug-drug interactions between bupropion and the CYP2D6-metabolized drug desipramine resulting in marked (5-fold) increases in desipramine exposure. Desipramine 157-168 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 18420781-7 2008 This work indicates that the reductive metabolites of bupropion are potent competitive CYP2D6 inhibitors in vivo and provides a mechanistic explanation for the clinical drug-drug interaction between bupropion and desipramine. Desipramine 213-224 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 87-93 17667959-3 2008 This retrospective single center study aimed to prove whether CYP2C19 and ample CYP2D6 genotyping (taking into consideration four null alleles and three decreased-activity alleles) could be used to predict imipramine and desipramine plasma concentrations in depressed patients, and whether genotype-based drug dose recommendations might assist in the early management of imipramine pharmacotherapy. Desipramine 221-232 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 80-86 17667959-5 2008 Desipramine and imipramine+desipramine plasma concentration per drug dose unit, imipramine dose at steady state, and imipramine dose requirement significantly depended on CYP2D6 genotype (Kruskal-Wallis test, P<0.0001). Desipramine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 171-177 17667959-5 2008 Desipramine and imipramine+desipramine plasma concentration per drug dose unit, imipramine dose at steady state, and imipramine dose requirement significantly depended on CYP2D6 genotype (Kruskal-Wallis test, P<0.0001). Desipramine 27-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 171-177 17667959-8 2008 Our protocol for CYP2D6 genotyping will thus importantly aid in the prediction of imipramine metabolism, allowing for the use of an adjusted starting dose and faster achievement of predefined imipramine+desipramine plasma levels in all genetic patient subgroups. Desipramine 203-214 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 17-23 18310890-5 2008 Imipramine, desipramine, mazindol, and GBR12909 competitively inhibited PROG 21-hydroxylation mediated by CYP2D4 and/or CYP2D6, and all psychotropic drugs inhibited ALLO 21-hydroxylation mediated by CYP2D4 and/or CYP2D6. Desipramine 12-23 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 120-126 18310890-5 2008 Imipramine, desipramine, mazindol, and GBR12909 competitively inhibited PROG 21-hydroxylation mediated by CYP2D4 and/or CYP2D6, and all psychotropic drugs inhibited ALLO 21-hydroxylation mediated by CYP2D4 and/or CYP2D6. Desipramine 12-23 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 213-219 18310890-6 2008 The inhibition constants (Ki values) of imipramine, desipramine, and mazindol against the 21-hydroxylation of PROG and ALLO by CYP2D6 were lower than those by CYP2D4. Desipramine 52-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 127-133 15802801-4 2005 The inhibitory effect of DMI on BF 1""-hydroxylation by human liver microsomal fractions or recombinant CYP2D6 was much lower than that on the hydroxylation by rat liver microsomes or CYP2D2. Desipramine 25-28 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 104-110 18974610-6 2008 In addition, the method was applied to the CYP2D6-mediated desipramine-quinidine interaction: the predicted 6.4-fold increase of desipramine AUC by quinidine was consistent with the observed 6.7-fold increase of AUC in the clinical drug-drug interaction study. Desipramine 59-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 43-49 18974610-6 2008 In addition, the method was applied to the CYP2D6-mediated desipramine-quinidine interaction: the predicted 6.4-fold increase of desipramine AUC by quinidine was consistent with the observed 6.7-fold increase of AUC in the clinical drug-drug interaction study. Desipramine 129-140 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 43-49 16680561-2 2007 The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects. Desipramine 93-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 70-76 16338282-9 2005 CONCLUSIONS: Low-dose ritonavir (100 mg twice daily) exerts a modest inhibitory effect on the activity of CYP2D6 in extensive metabolizers, as assessed with desipramine as the index substrate. Desipramine 157-168 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 106-112 15802801-2 2005 Inhibition was examined under the following two conditions: 1) DMI was co-incubated with BF and NADPH in the reaction mixture containing rat or human liver microsomes or yeast cell microsomes expressing rat CYP2D1, CYP2D2 or human CYP2D6 (co-incubation); 2) DMI was preincubated with NADPH and the same enzyme sources prior to adding the substrate (preincubation). Desipramine 63-66 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 231-237 15802801-9 2005 In contrast, human CYP2D6 may also biotransform DMI into some metabolite(s) that covalently bind to CYP2D6, but that do not inactivate the enzyme. Desipramine 48-51 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 19-25 15802801-9 2005 In contrast, human CYP2D6 may also biotransform DMI into some metabolite(s) that covalently bind to CYP2D6, but that do not inactivate the enzyme. Desipramine 48-51 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 100-106 16680870-1 2004 Clinically, cimetidine therapy impairs the clearance of various drugs metabolized by CYP2D6, such as desipramine and sparteine. Desipramine 101-112 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 85-91 15115913-0 2004 Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Desipramine 65-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 10-16 15115913-1 2004 This study utilized cytochrome P450 2D6 (CYP2D6) genotypes to explain variability of desipramine pharmacokinetics in a cohort of non-poor metabolizer individuals. Desipramine 85-96 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 20-39 15115913-1 2004 This study utilized cytochrome P450 2D6 (CYP2D6) genotypes to explain variability of desipramine pharmacokinetics in a cohort of non-poor metabolizer individuals. Desipramine 85-96 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 41-47 8938825-2 1996 The authors studied the effects of coadministration of desipramine, which is a substrate of CYP2D6, on plasma concentrations of bromperidol and its reduced metabolite (reduced bromperidol). Desipramine 55-66 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 92-98 9256169-6 1997 The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine). Desipramine 170-181 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-38 9256169-6 1997 The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine). Desipramine 170-181 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-37 9205822-1 1997 AIMS: In order to anticipate drug-interactions of potential clinical significance the ability of the novel antidepressant, venlafaxine, to inhibit CYP2D6 dependent imipramine and desipramine 2-hydroxylation was investigated in human liver microsomes. Desipramine 179-190 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 147-153 9205822-5 1997 The inhibitory effect of imipramine and desipramine on liver microsomal CYP2D6 dependent venlafaxine O-demethylation was determined similarly. Desipramine 40-51 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 72-78 9205822-10 1997 Imipramine and desipramine gave marked inhibition of CYP2D6 dependent venlafaxine O-demethylase activity (Ki values of 3.9 +/- 1.7 and 1.7 +/- 0.9 microM, respectively). Desipramine 15-26 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 53-59 9220124-3 1997 This review article will focus on basic pharmacokinetic considerations for elderly patients when psychotropics metabolized by CYP2D6, such as nortriptyline and desipramine, are prescribed. Desipramine 160-171 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 126-132 9220124-12 1997 Significant correlations have been reported between individual CYP2D6 activity and plasma concentrations of nortriptyline and desipramine. Desipramine 126-137 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 63-69 9049581-0 1997 Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Desipramine 90-101 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 48-54 9049581-1 1997 OBJECTIVE: The clinical relevance of the CYP2D6 oxidation polymorphism in the treatment of depression with desipramine (DMI) was studied prospectively in depressed outpatients. Desipramine 107-118 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 41-47 9049581-1 1997 OBJECTIVE: The clinical relevance of the CYP2D6 oxidation polymorphism in the treatment of depression with desipramine (DMI) was studied prospectively in depressed outpatients. Desipramine 120-123 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 41-47 14730412-0 2004 Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Desipramine 98-109 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 52-73 14610241-5 2004 Based on the potential of interaction from the in vitro experiments, drug interaction studies in healthy subjects were conducted using probe substrates for CYP2D6 (desipramine) in CYP2D6 extensive metabolizer subjects and CYP3A (midazolam) in CYP2D6 poor metabolizer subjects. Desipramine 164-175 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 156-162 14610241-5 2004 Based on the potential of interaction from the in vitro experiments, drug interaction studies in healthy subjects were conducted using probe substrates for CYP2D6 (desipramine) in CYP2D6 extensive metabolizer subjects and CYP3A (midazolam) in CYP2D6 poor metabolizer subjects. Desipramine 164-175 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 180-186 14610241-5 2004 Based on the potential of interaction from the in vitro experiments, drug interaction studies in healthy subjects were conducted using probe substrates for CYP2D6 (desipramine) in CYP2D6 extensive metabolizer subjects and CYP3A (midazolam) in CYP2D6 poor metabolizer subjects. Desipramine 164-175 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 180-186 12412819-0 2002 Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. Desipramine 70-81 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 118-137 12412819-0 2002 Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. Desipramine 70-81 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 139-145 12412819-1 2002 Terbinafine-CYP2D6 inhibition was evaluated by assessing 48-hour concentration-time profiles of the tricyclic antidepressant desipramine in 12 healthy volunteers identified as extensive cytochrome P450 2D6 (CYP2D6) metabolizers by genotyping and phenotyping. Desipramine 125-136 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 12-18 11417443-0 2001 Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Desipramine 49-60 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 15-21 11417443-1 2001 OBJECTIVE: Duplication of CYP2D6 causes very rapid metabolism of CYP2D6 substrates such as desipramine. Desipramine 91-102 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 26-32 11417443-1 2001 OBJECTIVE: Duplication of CYP2D6 causes very rapid metabolism of CYP2D6 substrates such as desipramine. Desipramine 91-102 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 65-71 11037800-2 2000 Desipramine is extensively metabolized by cytochrome P450 2D6 (CYP2D6), and kinetics of this compound are altered in poor metabolizers. Desipramine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 42-61 11037800-2 2000 Desipramine is extensively metabolized by cytochrome P450 2D6 (CYP2D6), and kinetics of this compound are altered in poor metabolizers. Desipramine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 63-69 10895986-0 2000 Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Desipramine 114-125 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 74-80 10895986-1 2000 We investigated the impact of the genotype of CYP2D6 on the hydroxylation of desipramine in eighteen patients who were administered desipramine hydrochloride per os. Desipramine 77-88 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 10895986-1 2000 We investigated the impact of the genotype of CYP2D6 on the hydroxylation of desipramine in eighteen patients who were administered desipramine hydrochloride per os. Desipramine 132-157 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 10895986-4 2000 The genotyping of CYP2D6 only grossly predicts the steady state concentration of desipramine, mainly predicts the risk of getting very high plasma levels. Desipramine 81-92 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 18-24 7604141-4 1995 These findings suggest that CBZ induces the 2-hydroxylation of DMI, a reaction primarily catalyzed by the polymorphic CYP2D6 isozyme. Desipramine 63-66 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 118-124 8848823-6 1996 These results suggest that PB is an inducer of the 2-hydroxylation of DMI, a reaction primarily catalyzed by CYP2D6, but do not provide further information on the specific P450 isoenzyme(s) being induced. Desipramine 70-73 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 109-115 8359181-7 1993 There was evidence for linkage between the CYP2D6 gene and the gene regulating the hydroxylation of desipramine and debrisoquine. Desipramine 100-111 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 43-49 8310712-14 1993 CYP2D6 catalyses C-hydroxylation of imipramine to 2-hydroxyimipramine more efficiently than its N-demethylation to desipramine. Desipramine 115-126 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 8335704-3 1993 In addition, however, the human CYP2D6 isozyme preparation was found to be unequivocally involved in the N-dealkylation of IMI to desmethylimipramine (DMI). Desipramine 130-149 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-38 8335704-3 1993 In addition, however, the human CYP2D6 isozyme preparation was found to be unequivocally involved in the N-dealkylation of IMI to desmethylimipramine (DMI). Desipramine 151-154 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-38 8513845-3 1993 This confirms that desipramine is extensively metabolized via the sparteine/debrisoquine oxidation polymorphism i.e. by CYP2D6. Desipramine 19-30 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 120-126 8513845-5 1993 The 5-fold decrease in clearance in EMs when desipramine was co-administered with paroxetine confirms that paroxetine is a potent inhibitor of CYP2D6. Desipramine 45-56 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 143-149 1346258-0 1992 Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Desipramine 59-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 16-22 1389951-7 1992 CYP2D6 activity was also diminished by the tricyclic antidepressant drugs clomipramine (2.2 microM), desipramine (2.3 microM) and amitriptyline (4.0 microM). Desipramine 101-112 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6